Stock ADVM ADVERUM BIOTECHNOLOGIES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Adverum Biotechnologies, Inc.

Equities

ADVM

US00773U2078

Real-time Estimate Cboe BZX
Other stock markets
 09:49:11 2024-04-18 am EDT 		5-day change 1st Jan Change
11.18 USD -1.50% Intraday chart for Adverum Biotechnologies, Inc. -5.72% +49.91%
Mar. 21 Adverum Biotechnologies Files $200 Million Mixed Shelf MT
Mar. 19 RBC Cuts Price Target on Adverum Biotechnologies to $2 From $3, Keeps Sector Perform, Speculative Risk MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Adverum Biotechnologies Files $200 Million Mixed Shelf
MT
RBC Cuts Price Target on Adverum Biotechnologies to $2 From $3, Keeps Sector Perform, Speculative Risk
MT
Adverum Biotechnologies: Q4 Earnings Snapshot
AQ
Adverum Biotechnologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Adverum Biotechnologies, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates
AQ
Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference
AQ
Adverum Biotechnologies, Inc. announced that it has received $127.5 million in funding from a group of investors
CI
Adverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
AQ
Transcript : Adverum Biotechnologies, Inc. - Special Call
Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD
AQ
Adverum Biotechnologies, Inc. Announces Positive Preliminary Efficacy and Safety Data from Luna Phase 2 Trial of Ixo-Cov in Patients with Wet AMD
CI
4D Molecular soars as mid-stage data for eye disease therapy 'checks all boxes'
RE
Adverum Biotechnologies Announces $127.5 Million Private Placement Financing
AQ
Adverum Biotechnologies, Inc. announced that it expects to receive $127.5 million in funding from a group of investors
CI
Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024
AQ
Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific Officer
AQ
Adverum Biotechnologies, Inc. Appoints Romuald Corbau as Chief Scientific Officer and Member of Executive Committee
CI
Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula Society
AQ
Adverum Biotechnologies to Participate in the Evercore ISI 6th Annual HealthCONx Conference
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ADVM Stock
  4. News Adverum Biotechnologies, Inc.